20+ years in Biologics R&D. Lead Biologics discovery, engineering, and early development. Drive therapeutic protein engineering ideas to in vivo proof of concept and milestone transitions. Manage CROs and CDMOs in Research and preclinical CMC development. Supported more than 10 major therapeutic protein and antibody programs to clinical development and FDA approval. 30 issued or published patents. 35 publications in peer-reviewed journals.
Huawei Qiu is a highly experienced professional with 29.5 years of work experience in biotechnology, protein chemistry, drug discovery, molecular biology, and protein engineering. Based in China, Huawei has a strong background in Biologics R&D and has led various research and development projects. They have supported major therapeutic protein and antibody programs to clinical development and FDA approval. Huawei has also received 30 patents and 35 publications in peer-reviewed journals. With a track record of success, Huawei has held key positions in renowned companies such as Palleon Pharmaceuticals, Xilio Therapeutics, Sanofi, and Genzyme.
China Resource Sanjiu Medical & Pharmaceutical is a pharmaceuticals company based out of SHENZHEN, GD | Guangdong, China.
Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.
Xilio is a Waltham, Massachusetts-based clinical-stage biopharmaceutical company focused on defeating cancer. The company’s proprietary technology enables the explosion of therapeutic activity specifically within the tumor while reducing toxicity throughout the body – a nod to the company name, Xilio, derived from the Latin term, Ex Nihilo, meaning creation or big-bang. Xilio is applying its technology to build a broad pipeline of engineered antibodies, cytokines and chemokines as potential new options for people living with cancer
We are Sanofi, an innovative global healthcare company. We chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
Boston's Brigham and Women's Hospital (BWH) is an international leader in virtually every area of medicine and has been the site of pioneering breakthroughs that have improved lives around the world. A major teaching hospital of Harvard Medical School, BWH has a legacy of excellence that continues to grow. With two outstanding hospitals, over 150 outpatient practices, and over 1,200 physicians, we serve patients from New England, throughout the United States, and from 120 countries around the world. The BWH name is a reflection of our history. In 1980 three of Boston’s oldest and most prestigious Harvard Medical School teaching hospitals - the Peter Bent Brigham Hospital, the Robert Breck Brigham Hospital, and the Boston Hospital for Women – merged to form Brigham and Women’s Hospital. As a national leader in improving health care quality and safety, we have helped to develop some of the industry’s best practices including computerized physician order entry (CPOE) to prevent medication errors. The CPOE is now a nationally-accepted safety practice. The BWH Biomedical Research Institute (BRI) is one of the most powerful biomedical research institutes in the world and the second largest recipient of National Institutes of Health (NIH) funding among independent hospitals in the United States. BWH has long had great success in research as measured by the number of important discoveries made, the size and scope of its research portfolio and the volume of publications annually. BWH is a training ground for physicians, nurses, and allied health professionals. We have 1,100 trainees in over 140 of the most sought after training programs in the world, and also host Harvard Medical School students in rotations throughout our programs. As our global health services expand, our clinical trainees have rich opportunities to contribute and learn in challenging environments around the world. Brigham and Women's Hospital is an EEO, AA, VEVRAA Employer.
Cranston,Rhode Island,United States
We found 1 Huawei Qiu's email addresses
We found 6 Huawei Qiu's phone numbers
Huawei Qiu's social media include: Linkedin,
Huawei Qiu works for GV20 Therapeutics
Huawei Qiu's role in GV20 Therapeutics is Senior Vice President Head Of Biologics Discovery
Huawei Qiu works in the industry of
Huawei Qiu's colleagues are
Huawei Qiu's latest job experience is Senior Vice President Head Of Biologics Discovery at GV20 Therapeutics
Huawei Qiu's latest education in Texas A&M University